NASDAQ:PSTV Plus Therapeutics (PSTV) Stock Price, News & Analysis $0.73 +0.05 (+7.14%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-1.26%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Plus Therapeutics Stock (NASDAQ:PSTV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Plus Therapeutics alerts:Sign Up Key Stats Today's Range$0.68▼$0.7550-Day Range$0.40▼$0.8352-Week Range$0.16▼$2.31Volume22.20 million shsAverage Volume39.02 million shsMarket Capitalization$72.58 millionP/E RatioN/ADividend YieldN/APrice Target$7.88Consensus RatingModerate Buy Company Overview Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases. The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors. Plus Therapeutics has secured orphan drug and rare pediatric disease designations for select compounds, reflecting its focus on addressing unmet needs in both adult and pediatric oncology. Clinical studies are conducted in collaboration with academic medical centers and contract research organizations across North America. Headquartered in Austin, Texas, Plus Therapeutics is led by an executive team with extensive experience in radiopharmaceuticals and oncology drug development. The company maintains research, manufacturing and administrative operations in the United States and continues to expand strategic partnerships to advance its targeted radiotherapeutic portfolio.AI Generated. May Contain Errors. Read More Plus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScorePSTV MarketRank™: Plus Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 262nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingPlus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPlus Therapeutics has a consensus price target of $7.88, representing about 977.0% upside from its current price of $0.73.Amount of Analyst CoveragePlus Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Plus Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Plus Therapeutics are expected to grow in the coming year, from ($2.30) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Plus Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Plus Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Plus Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.10% of the outstanding shares of Plus Therapeutics have been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently decreased by 12.66%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPlus Therapeutics does not currently pay a dividend.Dividend GrowthPlus Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.10% of the outstanding shares of Plus Therapeutics have been sold short.Short Interest Ratio / Days to CoverPlus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Plus Therapeutics has recently decreased by 12.66%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentPlus Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.Search Interest106 people have searched for PSTV on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows25 people have added Plus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 257% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Plus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $53,900.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.79% of the stock of Plus Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.28% of the stock of Plus Therapeutics is held by institutions.Read more about Plus Therapeutics' insider trading history. Receive PSTV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Plus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PSTV Stock News HeadlinesPlus Therapeutics (NASDAQ:PSTV) Earns Buy Rating from D. Boral CapitalSeptember 27, 2025 | americanbankingnews.comPlus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United HealthcareSeptember 26, 2025 | insidermonkey.comU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - which altcoins are positioned for massive gains and how to build the perfect portfolio.October 4 at 2:00 AM | Crypto 101 Media (Ad)D. Boral Capital Maintains Plus Therapeutics (PSTV) Buy RecommendationSeptember 25, 2025 | msn.comThese 3 Penny Stocks are Soaring Today: PLUS, EVAX, DVLTSeptember 25, 2025 | 247wallst.comPlus Therapeutics Pops on UNH PactSeptember 25, 2025 | baystreet.caPlus Therapeutics Shares Surge After UnitedHealthcare Coverage DealSeptember 25, 2025 | msn.comPlus Therapeutics stock soars after UnitedHealthcare agreementSeptember 25, 2025 | za.investing.comSee More Headlines PSTV Stock Analysis - Frequently Asked Questions How have PSTV shares performed this year? Plus Therapeutics' stock was trading at $1.15 at the start of the year. Since then, PSTV shares have decreased by 36.4% and is now trading at $0.7312. How were Plus Therapeutics' earnings last quarter? Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. The firm had revenue of $1.39 million for the quarter, compared to analysts' expectations of $1.08 million. When did Plus Therapeutics' stock split? Plus Therapeutics shares reverse split on Monday, May 1st 2023.The 1-15 reverse split was announced on Monday, May 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Plus Therapeutics? Shares of PSTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Plus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Plus Therapeutics investors own include Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO) and Adobe (ADBE). Company Calendar Last Earnings8/14/2025Today10/04/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PSTV CIK1095981 Webwww.plustherapeutics.com Phone737-255-7194Fax858-450-4335Employees20Year Founded1996Price Target and Rating Average Price Target for Plus Therapeutics$7.88 High Price Target$20.50 Low Price Target$3.00 Potential Upside/Downside+977.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.98 million Net Margins-357.85% Pretax Margin-357.85% Return on EquityN/A Return on Assets-117.72% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$5.82 million Price / Sales12.47 Cash FlowN/A Price / Cash FlowN/A Book Value($1.52) per share Price / Book-0.48Miscellaneous Outstanding Shares99,260,000Free Float98,481,000Market Cap$72.58 million OptionableNot Optionable Beta0.81 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:PSTV) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThese financial titans stride the earth, invisibleUBS says millionaire ranks have surged 5-fold — but many of these new millionaires aren’t tech moguls or Wall ...Porter & Company | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.